Navigation Links
For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm

Multaq Will Earn Decision Resources' Clinical Gold Standard Status for Atrial Fibrillation in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in maintenance of normal sinus rhythm in atrial fibrillation. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Multaq and celivarone, and Aryx Therapeutics' ATI-2042 have advantages in this attribute over propafenone (GlaxoSmithKline/Abbott's Rythmol/Rythmonorm, generics), the sales-leading antiarrhythmic agent in the market.

The new report entitled Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring also finds that an anticoagulant for the prevention of stroke in atrial fibrillation that does not require routine monitoring would earn a 53 percent patient share in the United States and a 55 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for the maintenance of normal sinus rhythm in atrial fibrillation was amiodarone (Sanofi-Aventis/Wyeth's Cordarone, generics). Based on available data and expert opinion, Multaq will earn gold standard status for maintenance of normal sinus rhythm in atrial fibrillation in 2012, following its approval for the indication in 2009. Additionally, following its approval in 2014, ATI-2042 will earn gold-standard status for the indication in 2017.

"Multaq and ATI-2042 have competitive advantages over other emerging therapies because they have been designed to have efficacy similar to that of amiodarone but without its side effects," said Decision Resources Analyst Samira Benyoucef, Ph.D. "Because they are free of thyroid and pulmonary toxicity--the main adverse effects constraining amiodarone's widespread use--Multaq and ATI-2042 offer a significant safety advantage over amiodarone."

About the Report

Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563               

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Larger Men at Greater Risk for Atrial Fibrillation
2. Big men more susceptible to atrial fibrillation
3. For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Austin, Texas, Physicians Second in Nation to Perform New Procedure for Difficult-to-Treat Atrial Fibrillation Cases
7. Increasing Use of Ablation to Treat Atrial Fibrillation
8. Defect in Gene Tied to Atrial Fibrillation
9. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
10. Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK
11. Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
Post Your Comments:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: